Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Premature Ejaculation Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Premature Ejaculation Overview | 7 | 1 |
| Premature Ejaculation Therapeutics under Development by Companies | 8 | 1 |
| Premature Ejaculation Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Premature Ejaculation Products under Development by Companies | 12 | 1 |
| Premature Ejaculation Companies Involved in Therapeutics Development | 13 | 5 |
| Allergan Plc | 13 | 1 |
| Ixchelsis Limited | 14 | 1 |
| NeuroHealing Pharmaceuticals Inc. | 15 | 1 |
| Plethora Solutions Holdings Plc | 16 | 1 |
| SK Chemicals Co., Ltd. | 17 | 1 |
| Premature Ejaculation Therapeutics Assessment | 18 | 10 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Combination Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 12 |
| (lidocaine + prilocaine) Drug Profile | 28 | 3 |
| IX-01 Drug Profile | 31 | 2 |
| modafinil Drug Profile | 33 | 1 |
| NCE-405 Drug Profile | 34 | 1 |
| onabotulinumtoxin A Drug Profile | 35 | 5 |
| Premature Ejaculation Dormant Projects | 40 | 1 |
| Premature Ejaculation Discontinued Products | 41 | 1 |
| Premature Ejaculation Product Development Milestones | 42 | 10 |
| Featured News &Press Releases | 42 | 1 |
| Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation | 42 | 1 |
| Nov 11, 2014: Plethora Solutions Provides Company Update | 42 | 1 |
| Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU | 43 | 1 |
| Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment | 44 | 1 |
| Mar 11, 2014: Plethora Solutions Provides Company update | 44 | 1 |
| Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation | 45 | 1 |
| Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation | 45 | 1 |
| Jul 01, 2013: AGM Statement &PSD502 Regulatory Update | 46 | 1 |
| Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update | 46 | 1 |
| Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502 | 47 | 1 |
| Dec 19, 2011: Plethora Provides Update On PSD502 | 48 | 1 |
| Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation | 48 | 1 |
| May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting | 49 | 1 |
| Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA) | 49 | 1 |
| Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program | 50 | 2 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |